Compare KBDC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | CERT |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | KBDC | CERT |
|---|---|---|
| Price | $14.00 | $6.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $15.40 | $12.22 |
| AVG Volume (30 Days) | 406.3K | ★ 3.3M |
| Earning Date | 03-02-2026 | 05-04-2026 |
| Dividend Yield | ★ 13.59% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 1.67 | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $193.84 | $5.05 |
| Revenue Next Year | $9.00 | $5.73 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $13.06 | $6.04 |
| 52 Week High | $16.89 | $15.38 |
| Indicator | KBDC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 35.76 |
| Support Level | $13.54 | $6.04 |
| Resistance Level | $14.33 | $7.52 |
| Average True Range (ATR) | 0.36 | 0.36 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 82.03 | 17.77 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.